Influenza Vaccination Guidelines

Universal Annual Vaccination Recommendation

• The American Academy of Pediatrics recommends annual influenza vaccination for everyone 6 months of age and older, regardless of risk status 1
• All persons aged 6 months and older should receive annual influenza vaccination, with no exceptions unless specific contraindications exist 1

Priority Populations Requiring Emphasis

• The Centers for Disease Control and Prevention (CDC) identifies high-risk medical groups, including all children aged 6 through 59 months, persons aged 50 years and older, and those with chronic conditions, as priority populations for influenza vaccination 1
• Immunocompromised persons, pregnant women, residents of nursing homes and long-term care facilities, persons with extreme obesity, and American Indian or Alaska Native persons are also considered high-risk populations 1
• Healthcare personnel and household contacts and caregivers of children under 5 years and persons with high-risk medical conditions should receive influenza vaccination to prevent transmission 1

Vaccination Frequency: Annual Administration

• Annual influenza vaccination is required due to antigenic drift, which causes circulating influenza strains to change annually, and waning immunity, which occurs over months 1
• The CDC recommends annual vaccination even when vaccine strains remain unchanged from the previous season due to immunity decline 2

Age-Specific Dosing Schedules

• Children who have received fewer than 2 total doses of influenza vaccine before July 1 of the current season require 2 doses administered at least 4 weeks apart, according to the Advisory Committee on Immunization Practices (ACIP) 1
• Children who have previously received 2 or more total doses require only 1 dose annually 3
• The American Academy of Pediatrics recommends that both doses be completed by the end of October to ensure protection before peak season 2

Optimal Timing

• Vaccination should begin as soon as vaccine becomes available, typically in early fall, and ideally be completed by the end of October, according to the CDC 2
• Vaccination should continue throughout the season as long as viruses are circulating and unexpired vaccine is available 4

Vaccine Selection

• The Inactivated Influenza Vaccine (IIV) is suitable for all persons 6 months and older and is preferred for immunocompromised persons, pregnant women, and those with contraindications to Live Attenuated Influenza Vaccine (LAIV) 1
• The LAIV is approved for healthy persons aged 2-49 years, but is not recommended for children under 2 years, those with recurrent wheezing, immunocompromised persons, pregnant women, or contacts of severely immunocompromised persons requiring protected environments 1

Annual Influenza Vaccination Necessity and Exceptions

Effectiveness of Prior Vaccination

• The CDC states that previous influenza vaccination does not provide meaningful protection against the strains circulating in the current season; therefore, all individuals aged ≥ 6 months should receive an influenza vaccine each year, irrespective of their vaccination history. 5

Duration of Vaccine‑Induced Immunity

• According to CDC guidance, antibody levels decline during the year after vaccination, leading to reduced immunity even when the vaccine composition remains unchanged; this waning is especially pronounced in elderly persons, who experience faster declines in antibody titers. 5

Contraindications to Annual Vaccination

• The CDC lists two specific contraindications that exempt individuals from the universal annual recommendation:

Annual Influenza Vaccination Guidelines for Children

Universal Recommendation

• The Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the Centers for Disease Control and Prevention (CDC) recommend that all children aged ≥ 6 months receive an annual influenza vaccine, irrespective of health status or risk factors. [7][8]9
• Antibody titers wane over the course of a year, so immunity declines even when vaccine strains remain unchanged, necessitating yearly revaccination. [7][8]

Dosing Schedule for Children Around 8 Years Old

• One dose per season is sufficient for a child who has previously received ≥ 2 influenza vaccine doses (any formulation) administered ≥ 4 weeks apart at any time before July 1 of the current season. The prior doses need not be from the same or consecutive seasons. 9
• Two doses (separated by at least 4 weeks) are required when the child’s vaccination history is unknown or insufficient (i.e., fewer than two prior doses ≥ 4 weeks apart before July 1). Both doses should be given even if the child turns 9 years old between the first and second dose. 9

Vaccine Selection

• Any licensed, age‑appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV4) may be used for children. 9
• For healthy children aged 2–49 years, the live attenuated influenza vaccine (LAIV) is an acceptable alternative to inactivated products. [10][11]
• The standard dose for children ≥ 3 years is 0.5 mL per injection. [10][11]

Immunogenicity Considerations

• The need for annual vaccination is driven by waning immunity: post‑vaccination antibody levels decline over the year, reducing protection even if the vaccine composition does not change. [7][8]

Evidence strength: The cited recommendations are based on national immunization guidelines (ACIP, AAP, CDC) and are considered strong (Level A) recommendations in the United States, although specific grading is not detailed in the source articles.

CDC Recommendations for Influenza Vaccination Timing, Populations, and Vaccine Selection

Timing of Vaccination

• Vaccination should continue throughout the entire influenza season as long as influenza viruses are circulating and unexpired vaccine is available, even after community influenza activity has been documented. 12
• In October, vaccination campaigns should prioritize high‑risk groups (persons > 50 years, children 6‑59 months, pregnant women, persons with chronic conditions, and healthcare workers); broader population vaccination can be extended into November and later weeks. [13][12]

Universal and High‑Risk Population Recommendations

• All individuals aged ≥ 6 months should receive an annual influenza vaccine, except those with severe allergy to vaccine components or a recent (within 6 weeks) Guillain‑Barré syndrome after a prior influenza vaccine. 14
• High‑risk groups that should be prioritized for vaccination include:
  
  • Children aged 6‑59 months. 12
  • Persons aged ≥ 50 years. 12
  • Pregnant women (all trimesters). 12
  • Individuals with chronic medical conditions such as asthma, chronic obstructive pulmonary disease, diabetes, heart disease, or immunocompromising disorders. 13
  • Healthcare personnel and household contacts/caregivers of high‑risk persons, including contacts of children < 5 years. 12

Inactivated Quadrivalent Vaccine (IIV4) – Indications

• IIV4 is recommended for all children aged 6‑23 months (LAIV4 not approved for this age). 13
• IIV4 is the preferred vaccine for pregnant women. 13
• IIV4 should be used in immunocompromised persons. 13
• IIV4 is indicated for individuals with asthma, chronic obstructive pulmonary disease, or cystic fibrosis. 13
• Children aged 2‑4 years with a history of recurrent wheezing should receive IIV4 (LAIV4 contraindicated due to increased risk of asthma/reactive airway disease). 13
• Persons aged ≥ 50 years should receive IIV4 (LAIV4 not approved for this age group). 13

Live‑Attenuated Intranasal Vaccine (LAIV4) – Eligibility and Safety

• LAIV4 is approved only for healthy individuals aged 2‑49 years without contraindications. [13][14]
• Eligibility criteria for LAIV4 include:
  
  • Age 2‑49 years. [13][14]
  • No chronic medical conditions (i.e., healthy status). 13
  • No history of recurrent wheezing in children aged 2‑4 years. 13
  • Not pregnant. 13
  • Not immunocompromised. 13
• Common adverse events observed with LAIV4:
  
  • In children and adolescents, runny nose/nasal congestion (28‑78%), headache (16‑44%), and sore throat (15‑27%) occur more frequently than with placebo. 13
  • In adults aged 18‑49 years, runny nose (44.5% vs 27.1% placebo), sore throat (27.8% vs 17.1% placebo), and tiredness/weakness (25.7% vs 21.6% placebo) are more common. 13

Dosing Volumes for IIV4 in Young Children

14

• For other quadrivalent formulations (Fluarix, Flucelvax, FluLaval), a uniform 0.5 mL dose is used for all ages ≥ 6 months (no specific citation provided).